We ؉ cells were collected with a median of two aphereses in 14 out of 17 patients; three failed to mobilize a number of CD34 ؉ cells adequate for subsequent manipulation. We found that in CR patients CD34
has been employed as the source of stem cells. However, due to the higher progenitor cell content, growth factorprimed PBSC are better than marrow cells in that they are able to speed engraftment and reduce transplant complications. 6, 7 Additionally, the large amount of progenitors makes easier the application of purging techniques with no substantial detriment of engraftment potential. In CLL, the mobilization of stem cells from the marrow to the peripheral blood may raise some concern, as patients have often received alkylating agents for a long time. 8 Moreover, clonal B cells are generally found in the bone marrow as well as in the peripheral blood even in patients in complete remission. 9 We have assessed the ability of CY 4 g/m 2 to mobilize PBSC and that of two different CD34
+ cell selection systems to deplete neoplastic cells from the apheresis samples in a series of 17 patients with poor prognosis CLL from three Italian centers enrolled in an autograft program. Our results show that PBSC yield is a function of disease response, and that the CD34 + cell selection method may play a key role in the autologous transplantation strategy.
Material and methods

Treatment protocol
Three Italian institutions participating in an ongoing autologous transplantation study have enrolled their patients since 1996. Both pretreated and untreated patients were eligible, provided they were р60 years of age, stage B(II), C(III) or C(IV) 10 (all stages when lymphocyte doubling time was р6 months), and had a performance (Karnofsky score) Ͼ80% and a normal cardiac, respiratory and liver function. Patients were required to sign an informed consent. The study was approved by the regional Bio-Ethical Committee.
Initial 
Patients characteristics and PBSC collection
There were 17 patients, 14 males and three females, with an age ranging from 36 to 63 years (median 54). The great majority (82%) were stage B(II), and 75% had у2 prior chemotherapy regimens. Eight were in CR and nine in PR at the time of PBSC mobilization (Table 1) .
For PBSC mobilization, a single intermediate dose (4 g/m 2 ) of CY was employed, followed by G-CSF 5 g/kg/day s.c. from the day that followed the CY infusion until the end of the apheretic collections. CY was delivered i.v. over 90 min followed by 1500 ml/m 2 hydration over the next 24 h. For urothelial protection, all patients were given sodium-2-mercapto-ethan-sulphonate (MESNA) i.v. every 4 h for three doses.
Circulating CD34 + cells were monitored daily from day 6 after CY treatment. Aphereses were started at hematologic recovery following the mobilization chemotherapy, as soon as CD34
+ cells in the peripheral blood reached a count of 20 × 10 6 /l. PBSC collections were initially planned to obtain, after the selection procedure and with a maximum of four apheretic runs, a number of CD34 + cells sufficient for stable engraftment according to individual center policy. This corresponded to at least 1 × 10 6 /kg CD34 + cells. When that target was not reached at the end of the immunoselection step, the patients were planned to undergo bone marrow harvest, with subsequent marrow cell selection employing the same methods and devices as for PBSC. When Ͻ1 × 10 6 /kg CD34 + cells were available both from bone marrow harvest and from apheretic collection, the patients went off-study.
For the apheretic collection of PBSC, either continuous or discontinuous flow devices were utilized, according to individual center availability. In general, 10 l of blood were processed daily with continuous flow devices, 6 l/day with discontinuous devices. Aphereses were run through the For flow cytometry estimation of CD34 + cells in blood and apheresis products the monoclonal antibody HPCA-2-FITC (Becton Dickinson, San Jose, CA, USA) was employed in a direct immunofluorescence assay, using large contiguous gates, as previously described. 12 Immune phenotype characterization of lymphoid cells in the apheresis products before and after CD34
+ cell selection was performed by direct immunofluorescence. Cells with a double CD5/CD20 fluorescence were also enumerated. For residual disease evaluation, a fraction of Ͼ5% lymphoid cells co-expressing CD5 and CD20 was assumed as evidence of disease persistence.
Positive selection and cryopreservation
Two different devices were used to positively select CD34 + cells and remove leukemic cells from the graft, the Ceprate SC stem cell concentrator (CellPro, Bothell, WA, USA) and the Isolex 300i (Baxter Biotech, Irvine, CA, USA). The former is based on the interaction between a biotinylated monoclonal antibody (MoAb) directed to the CD34 antigen and the avidin-coated beads in a column. The latter performs a selective binding of cells labeled with a murine anti-CD34 MoAb by means of magnetic beads coated with anti-mouse antibody. The cells are then magnetically separated. In general, to improve selection efficiency, the products of two to three aphereses were processed together, storing the first apheresis bag overnight at room temperature and pooling it with that of the subsequent procedures the following day. After selection, the samples were cryopreserved in 4% PBS-HSA and 7.5% DMSO before being stored in liquid nitrogen.
Molecular analysis
Molecular detection of CLL cells was performed by analysis of the clonal IgH gene rearrangement. For amplification and sequencing of the tumor VDJ region, BM and PB cells obtained during standard diagnostic procedures were separated on a Ficoll-Hypaque density gradient. DNA was obtained by cell lysis, phenol extraction and ethanol precipitation. Analysis of CDRIII rearrangements was performed by PCR amplification starting from genomic DNA and amplifications were performed as previously described. 13 Briefly, target DNA (1 g) was amplified in a PCR reaction with a degenerate consensus V(ACACGGC(C/T)(C/G) TGTATTACTGT) and J region (ACCTGAGGAGACGG-TGACC) oligoprimers in 50 l final volume comprising PCR buffer (Perkin Elmer-Cetus, Norwalk, CT, USA) 100 mM Tris-HCl, pH 8.3; 500 mM KCl, 2.5 mM MgCl 2 , 200 m of each of dATP, dCTP, dGTP, dTTP (Pharmacia, Biotech Italia, Cologno Monzes, Italy) and 2.5 units Amplitaq DNA polymerase (Perkin Elmer-Cetus). Samples were amplified by 'hot start' with initial denaturation at 94°C for 3 min followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, extension at 72°C for
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Results
Mobilization and apheretic collections
The results of PBSC mobilization and collection that followed treatment with CY and G-CSF are shown in Table  2 . In patient No. 10, CD34
+ cells failed to increase above the baseline value and aphereses were not initiated. In two patients (Nos 12 and 15) the apheretic program was interrupted before collecting a sufficient number of progenitor cells due to the decreasing level of CD34
+ cells in the peripheral blood. In both these cases, the aphereses had been started with some delay in comparison with the other patients.
After mobilization treatment, the CD34 + cells in the peripheral blood peaked to a median of 45.8 × 10 6 /l (range 4.5-109.3), with a 30-fold increase (range 2.9-666) above the baseline values. A median of two (range 2-4) leukaphereses per patient were run starting (median) 9 days after CY administration. The median CD34
+ cell yield was 3.6 × 10 6 /kg (range 0.5-12.8, Table 2 ). We tried to find a relationship between the height of the CD34 + cell peak and other clinical variables. No correlation was found with age, gender, number of previous chemotherapy regimens, time from last therapy to mobilization and disease status. Conversely, disease status correlated with the CD34 + cell yield of each single apheretic procedure (Wilcoxon non-parametric paired rank-sum test). In fact, the absolute number of CD34 + cells harvested was significantly higher in CR as compared to PR patients (P Ͻ 0.05).
CD34
+ cell selection
The results of CD34 + cell selection were analyzed as single procedures. A total of 16 procedures were carried out in 13 patients. Ten were performed with the Ceprate stem cell concentrator, and six with the Isolex 300i. The results are shown in Table 3 . In patient No. 12, the selection procedure was not done due to the inadequate number of CD34 + cells in the apheretic samples. The patient progressed and went off-study. In patient No. 13, immunoselection was not performed for technical reasons. In patient No. 15 collection was poor, with only 0.5 × 10 6 /kg CD34 + cells, and selection was omitted. The patient underwent a bone marrow harvest, but also marrow cells were insufficient for subsequent selection. In two other patients (Nos 8 and 11) marrow harvest was performed due to the low number of CD34 + cells (Ͻ1 × 10 6 /kg) recovered after the selection step. In both cases bone marrow cells were also subjected to selection and reinfused with PBSC at graft.
Results of the selection step are expressed either as recovery rate and purity of the cell population. Overall,
+ cell recovery was (median) 33.5% the pre-selection values (range 10-85). Final purity, expressed as percentage of CD34
+ cells in the sample, was 59% (range 22-94), with a CD5/20 + cell depletion of 2.7 log (range 1.
6-4.4). No correlation was found between CD34
+ cell recovery and number of nucleated cells, number and percentage of CD34 + and number of CD5/20 + cells charged on the selection device.
In terms of efficiency, the two selection devices, the Ceprate column and the Baxter Isolex 300i, performed quite differently. In fact, despite the apparent lack of other significant differences between the two groups of procedures, we obtained better results with the Baxter apparatus, both in terms of CD34
+ cell recovery and in terms of purity of the enriched cell fraction (P Ͻ 0.01 and P = 0.01, respectively, Table 4 ).
On PCR analysis, all evaluated graft samples showed persistence of the clonal IgH gene rearrangement both before and after immunoselection. This is an extremely sensitive technique, being able to detect a single neoplastic cell out of 10 5 . Up to now, only 12 out of the 17 patients have been autografted. They all received an immunoselected graft that contained a median of 2.25 × 10 6 /kg CD34 + cells. Three patients went off-study before being transplanted, the remainder are waiting for the autograft procedure. In those transplanted, engraftment occurred in all, with a median of 11 and 16 days to achieve ANC Ͼ0.5 × 10 9 /l and Ͼ25 × 10 9 /l platelets, respectively.
Discussion
As in other neoplastic diseases involving the bone marrow, autologous stem cell transplantation in CLL carries a risk of re-infusing tumor cells, and some studies suggest that malignant cells contaminating the graft may contribute to relapse. 14, 15 The techniques for in vitro tumor cell depletion that have been developed invariably result in a significant loss of progenitor cells, with consequent slower engraftment and increase of transplant complications. PBSC offer the advantage of a higher progenitor cell content in comparison with marrow. 16 This makes PBSC an ideal source when purging methods are employed.
In the present study, we evaluated the feasibility of PBSC mobilization, collection and immunoselection in patients with poor prognosis CLL. Most of the patients enrolled into the study had multiple prior chemotherapy treatments, and less than 50% could undergo the mobilization treatment already in complete remission. Nonetheless, our results show that even in pretreated patients PBSC can be successfully mobilized and harvested. In fact, we were able to collect a median of 3.6 × 10 6 /kg CD34 + cells. The results of mobilization were poor in only three patients. One failed to mobilize while in the remaining two the number of collected PBSC was considered too low for subsequent manipulation.
We observed a wide variation of results among patients, both in terms of PBSC peak value and in terms of number of collected PBSC (Table 2 ). When we tried to identify factors of mobilization and collection we found that disease
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+ mobilization and response rates the use of higher doses of CY (ie 7 g/m 2 ) could be advisable.
A total of 16 selection procedures were performed. Overall, the median CD34 + recovery after selection was 33.5%. But there was a wide variation of results, with procedures yielding as low as 10% the original (pre-selection) CD34 + cell number, and on the opposite side procedures with as high as 80% recovery. Both the number of progenitor cells recovered and the purity of CD34 + cell-enriched fraction were higher with the Baxter 300i than with the Ceprate device (P Ͻ 0.01 and P = 0.01, respectively), despite a comparable number and percentage of CD34 + and CD5/20 + cells processed. It seems that CD34 + cell enrichment using the magnetic beads performs better than the avidin-biotin immunoselection in terms of CD34 + cell purity and recovery, even if in three out of six procedures performed with the Isolex device, CD5/20 depletion was Ͻ2 log.
Our results confirm that the purging methods used in our study have some limitations. The main problem is that, together with tumor depletion, they may result in a considerable progenitor cell loss. Another limitation of tumor depletion is cost. 17 As suggested by Bensinger, and confirmed in the present analysis, people with the highest likelihood of neoplastic contamination of their graft may also be those with lowest CD34 + cell yields and will finally be ineligible for purification procedure.
We report a median of 2.7 log tumor cell depletion, and show that a single selection step markedly reduces, though does not eliminate, tumor contamination of the graft. Graft samples were PCR positive for the IgH gene rearrangement both before and after selection, irrespective of flow cytometric detection of leukemia cells. The efficacy of tumor depletion in these patients was therefore sub-optimal. To get a virtually tumor-free autograft an additional purging step could be necessary. 18, 19 Otherwise one may intensify treatment using higher doses of cyclophosphamide in the mobilization phase. Another approach could be represented by the use of a monoclonal antibody such as anti-CD20 that has shown clinical activity in non-Hodgkin's lymphoma, for an in vivo additional purging. 20 In conclusion, mobilization and harvesting of progenitor cells is feasible in CLL, but in a fraction of patients, and expecially in those failing chemotherapy, it may be difficult to obtain a sufficient number of PBSC for subsequent selection. The problem may be more difficult to solve if an inadequate selection method is available. The main issues to be addressed are the identification of patients who will fail the mobilization step and the improvement of laboratory methods for effective depletion of neoplastic cells with minimal progenitor loss.
